Generation Bio Co.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBIO research report →
Range $5 – $5.5
Price Chart
About the company
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina.
- CEO
- Yalonda Howze
- IPO
- 2020
- Employees
- 115
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on GBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.98M
- P/E
- -0.87
- Fwd P/E
- 10.08
- PEG
- -0.01
- P/S
- 3.25
- P/B
- 0.71
- EV/EBITDA
- -1.01
- Div Yield
- 0.00%
- Gross Margin
- 87.33%
- Op Margin
- -550.62%
- Net Margin
- -372.18%
- ROE
- -69.52%
- ROIC
- -56.92%
Latest fiscal year · YoY change
- Revenue
- $19.89M+236.9%
- Gross Profit
- $19.89M+236.9%
- Op Income
- $-142,390,000
- Net Income
- $-131,668,000-4.0%
- EPS
- $-19.76-0.7%
- OCF Growth
- -67.9%
- FCF Growth
- -51.2%
- 52W High
- $7.52
- 52W Low
- $3.00
- 50D MA
- $5.52
- 200D MA
- $5.11
- Beta
- 2.01
- RSI (14)
- 40
- Avg Volume
- 82.01K
No earnings-call transcripts are available for GBIO yet.
- Free Float
- 62.1%
- Shares Outstanding
- 6.74M
- Float Shares
- 4.19M
of shares held by institutions
40 13F filers
Buy/sell ratio 0.07. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 229.83K | 0 |
| Two Sigma Advisers, LP | 11.93K | ▲ 11.93K |
| First Horizon Advisors, Inc. | 2 | 0 |
Held by 1 ETFs
Biggest fund positions in GBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Atlas Venture Fund X, L.P. | other | 60 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 6,000 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 3,000 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 5,200 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 1,500 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 1,920 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 2,500 |
| Feb 9, 26 | Stehman-Breen Catherine | other | 4,752 |
| Feb 9, 26 | Rowland Charles A Jr | sell | 1,920 |
| Feb 9, 26 | Rowland Charles A Jr | sell | 6,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GBIO coverage
Recent articles, reports, and earnings notes.
No research on GBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GBIO report →Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
businesswire.com · Mar 15
Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages
defenseworld.net · Mar 1
Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25
defenseworld.net · Dec 19
Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders
prnewswire.com · Dec 15
GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders
businesswire.com · Dec 15
XOMA Royalty Enters into Agreement to Acquire Generation Bio
globenewswire.com · Dec 15
Generation Bio Announces Third Quarter 2025 Financial Results
globenewswire.com · Nov 5
Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)
defenseworld.net · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.